Lymphoma (including CLL)
H 8701; CD34-selection for ex vivo T-cell depletion of mobilized peripheral blood stem cells for recipients of HLA haploidentical related donor stem cell grafts receiving intensive conditioning (MOHEL): This study uses a monoclonal antibody and high dose chemotherapy and radiotherapy combined with haploidentical allogeneic stem cell transplantation to treat pediatric patients with hematologic malignancies.
H8713; Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients with Hematologic Malignancy, Using Haploidentical Family Donors and Sub-Myeloablative Conditioning with Campath 1H (HIMSUM): This study uses a monoclonal antibody, low dose chemotherapy and radiation combined with haploidentical allogeneic stem cell transplantation to treat patients with hematologic malignancies who have already received a stem cell transplant or who also have other complications such as kidney, liver, or heart disease.
H9936; Administration of LMP Specific Cytotoxic T-lymphocytes to Patients with Relapsed EBV-Positive Hodgkin’s disease (ALCI): This study uses allogeneic donor-derived EBV specific T-lymphocytes to treat EBV positive lymphoma
H17946: Administration of TGF- β Resistant LMP-Specific Cytotoxic T-Lymphocytes to Patients with Relapsed EBV-Positive Lymphoma (TGFbeta): This study uses EBV specific T-Lymphocytes with a gene inserted to render them resistant to TGF-β to treat EBV positive lymphoma.
H19384: Phase I Study Of CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin’s Lymphoma And Chronic Lymphocytic Leukemia (CRETI-NH): This study uses a chimeric antigen receptor (CAR) made from a monoclonal antibody called anti-CD19 that can kill kill tumor cells when it is expressed by T lymphocytes (CAR-T cells) These CAR T cells are used to treat non-Hodgkin’s lymphoma and CLL. The CAR also contains another component called CD28 that should enable the cells to last longer in the body and therefore be more effective.
H23637; Phase I/II Study of the Administration of Multi-Virus-Specific Cytotoxic T Lymphocytes (CTLs) Expressing CD19 Chimeric Receptors for Prophylaxis of Therapy of Relapse of CD19 Positive Malignancies Post Hematopoietic Stem Cell Transplantation (MULTIPRAT): This study uses a Chimeric Antigen Receptor (CAR) made from a monoclonal antibody that recognizes the CD19 molecule that is on B cell malignancies, and that is then expressed in a T cell that kills viruses (CAR-Virus specific T cell – CAR –VST) . The CAR-VSTs are used to prevent viral infections and cancer relapse following a stem cell transplant.
H23574; Phase I Study of Adoptive Transfer of Autologous T-lymphocytes Engrafted with a Chimeric Antigen Receptor Targeting the Kappa Light Chain of Immunoglobin Expressed in Patients with Chronic Lympocytic Leukemia or B-cell Lymphoma (CHARKALL): This study uses a chimeric receptor made from an antibody that recognizes the kappa light chain molecule present on non-Hodgkin lymphoma, multiple myeloma or chronic lymphocytic leukemia cancer cells that is expressed in T lymphocytes so that they become able to kill cancer cells. The CAR also contains another component called CD28 that should enable the cells to last longer in the body and therefore be more effective.
H26617; Phase I Study of the Administration of EBV CTLs Expressing CD30 Chimeric Receptors for Relapsed CD30+ Hodgkin’s Lymphoma and CD30+ Non-Hodgkin’s Lymphoma (CARCD30): This study uses a Chimeric Antigen Receptor (CAR) made from a monoclonal antibody that recognizes the CD30 molecule that is on Hodgkin lymphoma cells, and that is then expressed in a T lymphocyte that kills EBV infected cells. This combination targets Hodgkin lymphoma and some NHL that is CD30+ or EBV+ .
H27471; Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients with Active or Relapsed Hodgkin or Non-Hodgkin Lymphoma (TACTAL): This study uses T cells that have been trained to look for five (5) different proteins (called tumor associated antigens) that are frequently found on lymphoma cells. We hope these TAAs will help the CTLs find and kill lymphoma cells.
H27721; Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor for Relapsed CD30+ Hodgkin’s Lymphoma and CD30+ non-Hodgkin’s Lymphoma (CARTCD30): This study uses a Chimeric Antigen Receptor (CAR) made from a monoclonal antibody that recognizes the CD30 molecule that is on Hodgkin lymphoma cells, and that is then expressed in a T lymphocyte which can target Hodgkin lymphoma that is CD30+.
H30087; Treatment of B-COO with Autologous IL2 and CD40 Ligand Expressing Tumor Cells and Lenalidomide (TAIL): This study uses a tumor vaccine made from autologous tumor cells. The tumor vaccine is being given with drug lenalidomide which may help the vaccine work better in the body.
H28256; Inducible Caspase-9 Suicide Gene (DOTTI): This study uses haploidentical stem cells following conditioning. The stem cells have been transduced with a suicide gene that allows them to be destroyed if they cause Graft vs. Host Disease
H28361; Most Closely HLA-Matched Allogeneic LMP1/2-Specific Cytotoxic T Lymphocytes for Treatment of Patients with Relapsed EBV-Associated Diseases (MALTED): This study uses EBV specific T-lymphocytes generated from a donor to treat patients with EBV related disease.
H29617; Administration of Rapidly Generated LMP, BARF1 and EBNA1 Specific Cytotoxic T-Lymphocytes to Patients with EBV-positive Lymphoma (GRALE): This study uses autologous EBV specific T-Lymphocytes to treat lymphoma. Compared to some of our other similar studies, the cells used in this study are generated in the laboratory using a faster and simpler technique.